A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of 2 different durations of treatment with
pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen
(HBeAg)-negative chronic hepatitis B virus (HBV). It will also compare PEG-IFN alfa 2a
treatment alone and in combination with lamivudine (LAM). The anticipated time on study
treatment is 1-2 years, and the target sample size is 100-500 individuals.